PDGFB and neoplasm: Imatinib mesylate (IMA), a clinically approved drug for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor, has been successfully exploited to inhibit platelet-derived growth factor receptor-β (PDGF-β) signaling and reduce tumor IFP to improve small-molecule drug delivery for tumor therapy in animal models [18, 19].